Jocelyn Susan Chapman, MD
Obstetrics/Gynecology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 4
- Since medical school
- 18 years
- Boston University School of Medicine, 2008
Offices
4 locations · UCSF Medical Group Business Services · University of California Sfgh Medical Group · University of California San Francisco
Hospitals listed: Marinhealth Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chapman’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A110295 · Current
Licensed to practise in California · since 2009 · expires 2027-07-31 · Boston University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$213,035
Medicare paid this office $213,035 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 21 | $15,971 | $761 |
| Long return visit (40+ min) | 55 | $13,124 | $126 |
| New patient visit (60+ min) | 48 | $7,532 | $157 |
| Long return visit (40+ min) | 18 | $3,334 | $159 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 14 | $3,252 | $232 |
See all 10 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 21 | $15,971 | $761 |
| Long return visit (40+ min) | 55 | $13,124 | $126 |
| New patient visit (60+ min) | 48 | $7,532 | $157 |
| Long return visit (40+ min) | 18 | $3,334 | $159 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 14 | $3,252 | $232 |
| Return visit (30+ min) | 34 | $3,128 | $80 |
| Imaging of lymph nodes during surgery | 17 | $2,071 | $122 |
| Return visit (30+ min) | 12 | $1,581 | $122 |
| Short return visit (20+ min) | 21 | $1,235 | $59 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 17 | $216 | $11 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of the uterus | 27 | More than 96% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 23 | 13 | 11 | 23 | 26 | 21 |
| Imaging of lymph nodes during surgery | 12 | – | – | 13 | 21 | 17 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | – | – | – | 17 | 22 | 14 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 74 · Women 100% · Also on Medicaid 16% · Health risk score 1.80. Sicker patients than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 62% · Cancer 61% · Diabetes 21% · Depression 21% · Coronary heart disease 20% · Chronic kidney disease 18% · Atrial fibrillation 14% · Heart failure 11% · COPD 11%.
The office billed $1,496,255, Medicare allowed $268,825 and paid $213,035; for 6,193 services of 74 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 6,193 | 74 | 1.80 | $1,496,255 | $213,035 |
| 2023 | 139 | 874 | 73 | 1.74 | $770,089 | $113,672 |
| 2022 | 145 | 438 | 72 | 1.59 | $630,265 | $96,251 |
| 2021 | 130 | 349 | 73 | 1.60 | $446,248 | $71,382 |
| 2020 | 113 | 301 | 71 | 1.99 | $427,996 | $60,340 |
| 2019 | 122 | 346 | 71 | 1.54 | $519,763 | $75,625 |
| 2018 | 107 | 245 | 71 | 1.96 | $293,512 | $43,721 |
| 2017 | 127 | 334 | 71 | 1.63 | $314,603 | $48,923 |
| 2016 | 112 | 251 | 70 | 1.61 | $255,584 | $39,431 |
| 2015 | 61 | 93 | 71 | 1.70 | $86,720 | $12,751 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 26 | $20,763 | $799 |
| Long return visit (40+ min) | 48 | $12,367 | $127 |
| New patient visit (60+ min) | 40 | $6,443 | $161 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 22 | $5,120 | $233 |
| Long return visit (40+ min) | 16 | $3,517 | $160 |
| Return visit (30+ min) | 34 | $3,399 | $83 |
| Imaging of lymph nodes during surgery | 21 | $2,502 | $119 |
| Short return visit (20+ min) | 24 | $1,366 | $55 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 11 | $273 | $23 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 14 | $185 | $12 |
2022: 11 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 23 | $18,698 | $813 |
| Long return visit (40+ min) | 55 | $9,825 | $120 |
| New patient visit (60+ min) | 58 | $9,093 | $157 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 17 | $3,925 | $231 |
| Return visit (30+ min) | 30 | $2,625 | $82 |
| Long return visit (40+ min) | 12 | $2,150 | $154 |
| Imaging of lymph nodes during surgery | 13 | $1,636 | $126 |
| Return visit (30+ min) | 11 | $1,428 | $110 |
| Short return visit (20+ min) | 18 | $1,008 | $56 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 19 | $504 | $21 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 13 | $140 | $11 |
2021: 7 services
| Long return visit (40+ min) | 44 | $10,896 | $128 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 11 | $8,916 | $811 |
| New patient visit (60+ min) | 35 | $6,472 | $185 |
| Return visit (30+ min) | 32 | $3,252 | $81 |
| Long return visit (40+ min) | 11 | $1,897 | $172 |
| Return visit (30+ min) | 12 | $1,581 | $122 |
| Short return visit (20+ min) | 26 | $1,575 | $58 |
2020: 5 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 13 | $9,903 | $762 |
| Return visit (30+ min) | 53 | $5,120 | $68 |
| Long return visit (40+ min) | 34 | $5,104 | $100 |
| New patient visit (60+ min) | 33 | $5,048 | $153 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $92 | $8 |
2019: 7 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 23 | $16,993 | $739 |
| New patient visit (60+ min) | 42 | $6,052 | $144 |
| Return visit (30+ min) | 44 | $3,980 | $59 |
| Long return visit (40+ min) | 27 | $2,478 | $85 |
| Return visit (30+ min) | 21 | $2,126 | $101 |
| Imaging of lymph nodes during surgery | 12 | $1,418 | $118 |
| Short return visit (20+ min) | 12 | $608 | $43 |
2018: 5 services
| New patient visit (60+ min) | 22 | $3,179 | $145 |
| Return visit (30+ min) | 28 | $2,848 | $63 |
| Return visit (30+ min) | 22 | $2,432 | $87 |
| Long return visit (40+ min) | 14 | $1,724 | $91 |
| Short return visit (20+ min) | 14 | $575 | $36 |
2017: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $4,477 | $93 |
| New patient visit (60+ min) | 26 | $3,614 | $139 |
| Return visit (30+ min) | 28 | $3,307 | $66 |
| Return visit (30+ min) | 20 | $2,492 | $92 |
| Short return visit (20+ min) | 40 | $2,058 | $37 |
| New patient visit (45+ min) | 11 | $1,268 | $115 |
| Short return visit (20+ min) | 14 | $1,193 | $63 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,680 | $92 |
| Return visit (30+ min) | 29 | $2,375 | $59 |
| Short return visit (20+ min) | 50 | $2,244 | $35 |
| New patient visit (45+ min) | 11 | $1,035 | $94 |
2015: 2 services
| Short return visit (20+ min) | 37 | $1,783 | $45 |
| Return visit (30+ min) | 16 | $1,415 | $71 |
Medicaid work
$764 in 2021
Medicaid paid $764 for 12 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EMERGENCY DEPARTMENT VISIT MAY NOT REQ PHYS/QHP | 12 | $764 |
| 2021 | 12 | 1 | 12 | $764 |
| 2020 | 27 | 2 | 14 | $1,261 |
| 2019 | 25 | 1 | 13 | $1,340 |
See the largest Medicaid services in earlier years
2020
| Return visit (30+ min) | 13 | $1,182 |
| Telehealth transmission, per minute, professional services bill separately | 14 | $79 |
2019
| Return visit (30+ min) | 25 | $1,340 |
Drugs they prescribed that Part D paid
$1,126,807
Pharmacies billed $1,126,807 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 12% of their Part D prescriptions (37 of 318) in 2024. A higher opioid share than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0%.
239 generic and 79 brand-name prescriptions · $1,126,807 in drug cost · 44 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lynparza | 48 | $663,980 | $13,833 |
| Zejula | 15 | $345,891 | $23,059 |
| Ondansetron | 31 | $505 | $16 |
| Ibuprofen | 57 | $433 | $8 |
| Dexamethasone | 16 | $319 | $20 |
See all 9 drugs
| Lynparza | 48 | $663,980 | $13,833 |
| Zejula | 15 | $345,891 | $23,059 |
| Ondansetron | 31 | $505 | $16 |
| Ibuprofen | 57 | $433 | $8 |
| Dexamethasone | 16 | $319 | $20 |
| Neomycin Sulfate | 19 | $118 | $6 |
| Metronidazole | 22 | $107 | $5 |
| Oxycodone | 34 | $80 | $2 |
| Gabapentin | 20 | $58 | $3 |
Year by year
| 2024 | 318 | 91 | 12% (37) | 25% | $1,126,807 |
| 2023 | 280 | 76 | 14% (38) | 19% | $639,697 |
| 2022 | 262 | 71 | 10% (25) | 17% | $300,184 |
| 2021 | 232 | 67 | 13% (30) | 16% | $265,424 |
| 2020 | 241 | 60 | 10% (25) | 21% | $479,457 |
| 2019 | 277 | 63 | 12% (33) | 18% | $414,867 |
| 2018 | 189 | 49 | 12% (22) | None | $147,849 |
| 2017 | 140 | 44 | 19% (26) | 9% | $54,511 |
| 2016 | 76 | 26 | None | None | $24,012 |
| 2015 | 39 | 19 | None | None | $12,743 |
| 2013 | 18 | None | None | None | $5,743 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Lynparza | 33 | $384,989 | $11,666 |
| Ondansetron | 30 | $534 | $18 |
| Dexamethasone | 19 | $350 | $18 |
| Ibuprofen | 41 | $294 | $7 |
| Prochlorperazine Maleate | 18 | $192 | $11 |
| Oxycodone | 36 | $51 | $1 |
| Gabapentin | 20 | $47 | $2 |
| Metronidazole | 11 | $23 | $2 |
2022: 11 drugs
| Zejula | 12 | $175,289 | $14,607 |
| Lynparza | 11 | $108,952 | $9,905 |
| Estradiol (Twice Weekly) | 12 | $755 | $63 |
| Ondansetron | 24 | $366 | $15 |
| Ibuprofen | 49 | $324 | $7 |
| Dexamethasone | 20 | $307 | $15 |
| Prochlorperazine Maleate | 16 | $208 | $13 |
| Gabapentin | 26 | $183 | $7 |
| Oxycodone | 25 | $72 | $3 |
| Neomycin Sulfate | 12 | $70 | $6 |
| Metronidazole | 13 | $34 | $3 |
2021: 6 drugs
| Zejula | 20 | $257,258 | $12,863 |
| Dexamethasone | 15 | $440 | $29 |
| Ibuprofen | 35 | $277 | $8 |
| Ondansetron | 20 | $256 | $13 |
| Gabapentin | 26 | $117 | $4 |
| Oxycodone | 25 | $69 | $3 |
2020: 9 drugs
| Lynparza | 12 | $182,681 | $15,223 |
| Zejula | 12 | $163,138 | $13,595 |
| Xarelto | 11 | $5,410 | $492 |
| Ondansetron | 31 | $528 | $17 |
| Dexamethasone | 15 | $413 | $28 |
| Prochlorperazine Maleate | 20 | $234 | $12 |
| Ibuprofen | 28 | $205 | $7 |
| Gabapentin | 28 | $138 | $5 |
| Oxycodone | 23 | $109 | $5 |
2019: 11 drugs
| Lynparza | 13 | $196,946 | $15,150 |
| Zejula | 13 | $172,923 | $13,302 |
| Xarelto | 11 | $5,149 | $468 |
| Ondansetron | 29 | $532 | $18 |
| Dexamethasone | 11 | $304 | $28 |
| Ibuprofen | 32 | $246 | $8 |
| Oxycodone | 32 | $126 | $4 |
| Prochlorperazine Maleate | 15 | $125 | $8 |
| Gabapentin | 23 | $95 | $4 |
| Metronidazole | 11 | $28 | $3 |
| Ibu | 12 | $27 | $2 |
2018: 6 drugs
| Ondansetron | 23 | $338 | $15 |
| Oxycodone | 18 | $151 | $8 |
| Dexamethasone | 12 | $144 | $12 |
| Prochlorperazine Maleate | 18 | $111 | $6 |
| Ibuprofen | 17 | $110 | $6 |
| Ibu | 12 | $59 | $5 |
2017: 3 drugs
| Oxycodone | 23 | $322 | $14 |
| Ibuprofen | 23 | $109 | $5 |
| Prochlorperazine Maleate | 11 | $81 | $7 |
2016: 2 drugs
| Tamoxifen Citrate | 11 | $376 | $34 |
| Gabapentin | 13 | $179 | $14 |
Money from drug and device companies
$206 in 2025
| 2025 | 3 | 3 | None | $206 |
| 2024 | 1 | 1 | None | $56 |
| 2021 | 1 | 1 | None | $111 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $102 | 1 payment
|
| GlaxoSmithKline | None | $55 | 1 payment
|
| Boston Scientific | Spaceoar Vue System - 10ml | $49 | 1 payment
|
See all 3 published payments
| Boston Scientific | Meals · 2025-12-16 | Spaceoar Vue System - 10ml | $49 |
| GlaxoSmithKline | Meals · 2025-06-19 | None | $55 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Lynparza | $102 |
See earlier years (2024, 2021)
2024: $56
| Ethicon US | Harmonic | $56 | 1 payment
|
2021: $111
| GlaxoSmithKline | Zejula | $111 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Verastem, Inc. · Ramp 301 - Gog-3097 · 2025 | Their institution | $21,251 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1770810590
- Licence
- CA A110295California A110295: Current · expires 2027-07-31
- Trained
- Boston University School of Medicine, 2008 · 18 years ago
- Group
- UCSF Medical Group Business Services · University of California Sfgh Medical Group · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1825 4th St, San Francisco, CA, 94143
- NPI first listed
- 2009-11-16
- NPI last updated
- 2019-03-06
This is when the NPI record was last certified, not a medical board exam.